I know it's early in the process, but do you see this as a replacement for traditional chemotherapy, immunotherapy, radiation, or in conjunction with some of those other therapies? Is it too early to say?

I think both.

I think both.

Uh, what we're seeing in our Phase 3 is we are testing our drug, uh, alone, a, a local therapy to treat disease.

Again, that's kind of an unprecedented, uh, you know, result that we've seen.

Uh, uh, uh, against the standard of care chemotherapy in metastatic sarcoma.

So our drug head-to-head, hopefully we have the superiority there.

Before I let you go today, tell us a little bit about your background and the development of Intensity Therapeutics and w- how you sort of took your career and really shifted it into this other great dimension.